R
Rachel Richardson
Researcher at University of Oxford
Publications - 4
Citations - 800
Rachel Richardson is an academic researcher from University of Oxford. The author has contributed to research in topics: Antigen & Vaccination. The author has an hindex of 4, co-authored 4 publications receiving 690 citations.
Papers
More filters
Journal ArticleDOI
CD161 ++ CD8 + T cells, including the MAIT cell subset, are specifically activated by IL-12+IL-18 in a TCR-independent manner
James E. Ussher,Matthew Bilton,Emma Attwod,Jonathan Shadwell,Rachel Richardson,Catherine de Lara,Elisabeth Mettke,Ayako Kurioka,Ted H. Hansen,Paul Klenerman,Paul Klenerman,Christian B. Willberg,Christian B. Willberg +12 more
TL;DR: The data show that CD161++ T cells are the predominant T‐cell population that responds directly to IL‐12+IL‐18 stimulation, and broaden the potential role of MAIT cells beyond bacterial responsiveness to potentially include viral infections and other inflammatory stimuli.
Journal ArticleDOI
A human vaccine strategy based on chimpanzee adenoviral and MVA vectors that primes, boosts, and sustains functional HCV-specific T cell memory.
Leo Swadling,Stefania Capone,Richard D Antrobus,Anthony Brown,Rachel Richardson,Evan W. Newell,Evan W. Newell,John Halliday,John Halliday,Christabel Kelly,Christabel Kelly,Dan Hameiri Bowen,Joannah R. Fergusson,Ayako Kurioka,Virginia Ammendola,Mariarosaria Del Sorbo,Fabiana Grazioli,Maria Luisa Esposito,Loredana Siani,Cinzia Traboni,Adrian V. S. Hill,Stefano Colloca,Mark M. Davis,Alfredo Nicosia,Riccardo Cortese,Antonella Folgori,Paul Klenerman,Paul Klenerman,Eleanor Barnes,Eleanor Barnes +29 more
TL;DR: A first-in-human trial of a prime-boost vaccine strategy for HCV, with durable, broad, sustained, and balanced T cell responses, characteristic of those associated with viral control, paving the way for the first efficacy studies of a prophylactic HCV vaccine.
Journal ArticleDOI
Chronic hepatitis C viral infection subverts vaccine-induced T-cell immunity in humans.
Christabel Kelly,Leo Swadling,Stefania Capone,Anthony Brown,Rachel Richardson,John Halliday,Annette von Delft,Ye Htun Oo,David Mutimer,Ayako Kurioka,Felicity Hartnell,Jane Collier,Virginia Ammendola,Mariarosaria Del Sorbo,Fabiana Grazioli,Maria Luisa Esposito,Stefania Di Marco,Loredana Siani,Cinzia Traboni,Adrian V. S. Hill,Stefano Colloca,Alfredo Nicosia,Riccardo Cortese,Antonella Folgori,Paul Klenerman,Eleanor Barnes +25 more
TL;DR: Vaccination with potent HCV adenoviral vectored vaccines fails to restore T‐ cell immunity except where there is genetic mismatch between vaccine immunogen and endogenous virus; this highlights the major challenge of overcoming T‐cell exhaustion in the context of persistent antigen exposure with implications for cancer and other persistent infections.
Journal ArticleDOI
Highly-Immunogenic Virally-Vectored T-cell Vaccines Cannot Overcome Subversion of the T-cell Response by HCV during Chronic Infection.
Leo Swadling,John Halliday,Christabel Kelly,Anthony Brown,Stefania Capone,M. Azim Ansari,David Bonsall,Rachel Richardson,Felicity Hartnell,Jane Collier,Virginia Ammendola,Mariarosaria Del Sorbo,Annette von Delft,Cinzia Traboni,Adrian V. S. Hill,Stefano Colloca,Alfredo Nicosia,Riccardo Cortese,Paul Klenerman,Antonella Folgori,Eleanor Barnes +20 more
TL;DR: In conclusion, vaccination with ChAd3-NSmut and MVA-N Smut prime/boost, a potent vaccine regimen previously optimized in healthy volunteers was unable to reconstitute HCV-specific T-cell immunity in HCV infected patients.